have been published (Hayward et al., 1988; Gerhard et al., 1987) . The contradiction may be partly because of the control group used. It is important that the patient and control groups be matched for ethnicity, and that the controls have passed through most of their age of risk. In this way it is possible to maximise the difference in cancer risk between the two groups, and therefore the chance of finding an association between an allele and the development of a tumour.
Such an association may exist because certain alleles are more susceptible to transformation by particular carcinogens.
Alternatively, certain alleles may have greater transformation potential after activation. In both cases, individuals with a high genetic risk could be subjected to appropriate medical surveillance.
Most studies in this area have analysed the frequencies of c-Ha-ras restriction fragment length polymorphisms (RFLPs) although polymorphisms have been identified at many other proto-oncogene loci. Most reports have been concerned with solid tumours rather than haematopoietic neoplasms. In contrast, we have explored the genetic variation of two protooncogenes, c-myb and L-myc, in non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. C-myb is the transforming gene of the avian myeloblastosis virus (AMV). The product of the gene is a nuclear DNA binding protein (Moelling et al., 1985) . It is expressed in haematopoetic cells of all lineages (Westin et al., 1982) and for this reason may play a role in the differentiation and transformation of these cells. An EcoRI RFLP of c-myb has been described (Dozier et al., 1986) but there have been no reports of the allele frequencies in patients with haematopoietic cancers. L-myc is a member of the myc family of oncogenes and may, like c-myc, be a DNA-binding protein (DePinho et al., 1987) . Nau et al. (1985) reported an EcoRI RFLP of L-myc which has subsequently been found to have a significant association with the extent of lung and renal cell cancer metastases (Kawashima et al., 1988; Kakehi & Yoshida, 1989) . In both cases the S allele is significantly associated with metastases. We wished to test whether specific alleles of c-myb and L-myc are associated with non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL). Although it is thought that the aetiologies of these two diseases may be similar (Berard, 1981) (range 7-88 years) , and for the six ALL patients was 2.3 years (range 1-4 years). The diagnosis of all patients was confirmed by histopathology. All the individuals in the study were of European extraction. Southern blotting was carried out by the alkaline transfer method (Reed & Mann, 1985) and the blots were hybridised with radiolabelled L-myc and c-myb probes (Nau et al., 1985; Dozier et al., 1986) (Figures 1 and 2, Tables I and II) . In both cases we detected the RFLPs as reported (Nau et al., 1985; Dozier et al., 1986) ( Figures I and 2 ). In addition all blots were hybridised separately with radiolabelled pUC DNA to distinguish genetic variation from plasmid contamination (data not shown). As a further control, the blots were hybridised to a c-mos probe (which gives a single band in 98% of individuals) to rule out partial digestion as opposed to genetic variation (Chenevix-Trench et al., 1989) .
The genotype frequencies for c-myb were homogeneous between the two control groups, between the two patient groups and between the pooled patient versus the pooled control groups. Neither was there a significant difference in the c-myb gene frequencies between the two patient groups (X2 = 0.904; 0.3 <P <0.5), or between the two control groups (X2 =0.002; P>0.95). Hence these could be pooled to compare the frequencies in the total patient group versus the total control group. The differences were not significant (X2 = 0.149; 0.5 <P<0.7), thereby providing no evidence that this c-myb polymorphism is involved in the aetiology of lymphoma and leukaemia.
The L-myc data are more complicated (Table II 2= 0.149; 0.5 <P <0.7) and the unselected controls alone (since they are more alike in age to our cancer groups). We then find that the difference is significant (x2 = 5.19; 0.02 < P <0.05) with the S allele being more common in the cancer patients. This implies that the S allele might be one factor which confers a greater susceptibility to haematopoietic cancer, just as it appears to influence lung and renal cancer metastasis (Kawashima et al., 1988; Kakehi & Yoshida, 1989 Among the NHL patients there was no assbociation between the presence of either L-myc or c-myb allele and a positive family history of cancer (data not shown). Pooled across all patient and control groups, we estimate that the frequency of the c-myb Al allele is 0.432 ± 0.023 and that the frequency of the L-myc L allele is 0.485 ± 0.021. Goodness of fit tests show that both these proto-oncogenes are in Hardy-Weinberg equilibrium (for c-myb X2 = 0.047, 0.8 < P < 0.9; and for L-myc X2 = 3.06, 0.05 < P < 0.1). This would be compatible with a neutral polymorphism which does not affect fitness, or in the case of L-myc, with a balanced polymorphism maintained by opposing selection factors. However, it is worth noting that although the Hardy-Weinberg test is notoriously insensitive to selection pressures, the L-myc data are approaching a significant divergence from equilibrium which may indicate that some undirectional selection, or migration, exists.
Lack of an association between a particular allele and a disease state does not of course mean that the gene has no role in the predisposition to the disease. For such an association to be detected, the RFLP must detect the predisposing mutation iteself or be in tight linkage disequilibrium with it. In addition because NHL and ALL are biologically and probably aetiologically heterogeneous, the fact that we have pooled together subtypes of these diseases might have concealed a significant association with particular subtypes. Our samples were too small to treat the subtypes independently. Therefore, in conclusion, we have no evidence that this RFLP of the c-myb locus plays a role in susceptibility to NHL and ALL although we cannot rule it out. We have tentative evidence that variation at the L-myc locus plays a role both in survival to old age, and in susceptibility to these haematopoietic cancers. However, this result could be due to sampling fluctuation and should be treated with caution until replicated.
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